Loading stock data…
PCVX
$56.93-0.31 (-0.54%)
Market ClosedLast close May 1
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vaxcyte, Inc. in the Healthcare sector is trading at $56.93. The stock is currently 12% below its 52-week high of $65.00, remaining 23.3% above its 200-day moving average. Technical signals show oversold RSI of 29 and bearish MACD signal, explaining why PCVX maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 29) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$56.93
Potential Upside
5%
Whystock Fair Value$59.78
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$109.00+91.5%
Range$67.00 – $163.00
Fundamentals
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.69B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.39%
Volume
Today's trading volume
697,211
Recent News
Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage
Vaxcyte Inc (NASDAQ:PCVX) is among the best 52-week high US stocks to buy. Vaxcyte Inc (NASDAQ:PCVX) has completed enrollment in a pair of Phase 3 clinical trials evaluating its vaccine candidate VAX-31. The company announced this development on March 23, stating that it enrolled approximately 4,000 participants in the OPUS-1 trial and 1,300 in the […]
Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?
If you are wondering whether Vaxcyte's share price still offers value after a strong run, this breakdown will help you connect the recent moves to what the business may be priced for today. The stock last closed at US$60.88, with returns of 4.3% over 7 days, 5.8% over 30 days, 31.0% year to date and 95.1% over the past year. This means the current price reflects a lot of recent optimism and changing risk perceptions. Recent coverage has focused on Vaxcyte's position within the US...
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)?
Vaxcyte, Inc. reported a full-year 2025 net loss of US$766.63 million, with basic loss per share from continuing operations of US$5.63, and simultaneously moved to strengthen its balance sheet through a US$408.10 million follow-on equity raise and an additional US$500 million at-the-market program. Alongside these financing steps, Vaxcyte filed a US$473.86 million shelf registration tied to employee stock plans and advanced its VAX-31 pneumococcal vaccine program into multiple late-stage...
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.
For growth-focused biotech investors, Vaxcyte is no longer just a science story.